Asymmetric reduction of prochiral ketones to chiral alcohols catalyzed by plants tissue

As an important organic compound, chiral alcohols are the key chiral building blocks to many single enantiomer pharmaceuticals. Asymmetric reduction of the corresponding prochiral ketones to produce the chiral alcohols by biocatalysis is one of the most promising routes. Asymmetric reduction of different kinds of non-natural prochiral ketones catalyzed by various plants tissue was studied in this work. Acetophenone, 4'-chloroacetophenone and ethyl 4-chloroacetoacetate were chosen as the model substrates for simple ketone, halogen-containing aromatic ketone and beta-ketoesters, respectively. Apple (Malus pumila), carrot (Daucus carota), cucumber (Cucumis sativus), onion (Allium cepa), potato (Soanum tuberosum), radish (Raphanus sativus) and sweet potato (Ipomoea batatas) were chosen as the biocatalysts. It was found that these kinds of prochiral ketoness could be reduced by these plants tissue with high enantioselectivity. Both R- and S-form configuration chiral alcohols could be obtained. The e.e. and chemical yield could reach about 98 and 80% respectively for acetophenone and 4'-chloroacetophenone reduction reaction with favorable plant tissue. And the e.e. and yield for ethyl 4-chloroacetoacetate reduction reaction was about 91 and 45% respectively.     

Stem cells, vascular smooth muscle cells and atherosclerosis

Stem cells have the ability to differentiate into a variety of cells to replace dead cells or to repair tissue. Recently, accumulating evidence indicates that mechanical forces, cytokines and other factors can influence stem cell differentiation into vascular smooth muscle cells (SMCs). In developmental process, SMCs originate from several sources, which show a great heterogenicity in different vessel walls. In adult vessels, SMCs display a less proliferative nature, but are altered in response to risk factors for atherosclerosis. Traditional view on SMC origins in atherosclerotic lesions is challenged by the recent findings that stem cells and smooth muscle progenitors contribute to the development of atherosclerotic lesions. Vascular progenitor cells circulating in human blood and the presence of adventitia in animals are recent discoveries, but the source of these cells is still unknown. The present review gives an update on the progress of stem cell and SMC research in atherosclerosis, and discusses possible mechanisms of stem/progenitor cell differentiation that contribute to the disease process.     

Downstream bioprocessing of human pluripotent stem cell‐derived therapeutics

With the advancement in lineage‐specific differentiation from human pluripotent stem cells (hPSCs), downstream cell separation has now become a critical step to produce hPSC‐derived products. Since differentiation procedures usually result in a heterogeneous cell population, cell separation needs to be performed either to enrich the desired cell population or remove the undesired cell population. This article summarizes recent advances in separation processes for hPSC‐derived cells, including the standard separation technologies, such as magnetic‐activated cell sorting, as well as the novel separation strategies, such as those based on adhesion strength and metabolic flux. Specifically, the downstream bioprocessing flow and the identification of surface markers for various cell lineages are discussed. While challenges remain for large‐scale downstream bioprocessing of hPSC‐derived cells, the rational quality‐by‐design approach should be implemented to enhance the understanding of the relationship between process and the product and to ensure the safety of the produced cells.     

Highly efficient synthesis of alternate alpha- and beta-(1-->3)-linked glucose hepta- and octasaccharides

Two heptasaccharides alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-beta-D-Glcp-1-OMP and beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp1-OMP, and two octasaccharides alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp-1-OMP and beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-alpha-D-Glcp-(1-->3)-beta-D-Glcp-(1-->3)-beta-D-Glcp1-OMP were synthesized in a stereospecific way by remote control.     

抗大麦黄矮病的小偃麦易位系的创制与鉴定

抗大麦黄矮病的小偃麦易位系的创制与鉴定@辛志勇$中国农业科学院作物育种载培研究所!北京100081@张增燕$中国农业科学院作物育种载培研究所!北京100081@陈孝$中国农业科学院作物育种载培研究所!北京100081@林志珊$中国农业科学院作物育种载培研究所!北京100081大麦;;小偃麦;;易位系     

贵州产五步蛇蛇毒磷脂酶A2的抗凝血及抗血栓作用研究

目的研究贵州产五步蛇蛇毒磷脂酶Ａ２的抗凝血及抗血栓作用。方法对大鼠静脉注射不同剂量的ＰＬＡ２,测定大鼠的凝血时间、凝血酶原时间、抗凝效价和血栓抑制率。结果ＰＬＡ２浓度达到１．０ｍｇ／ｋｇ以上,能显著延长大鼠凝血时间及凝血酶原时间,其抗凝效价相当于肝素钠的２４．８％～３１．５％。ＰＬＡ２能显著抑制大鼠实验性动脉及静脉血栓的形成。结论贵州产五步蛇ＰＬＡ２具有较强的抗凝血和抗血栓作用。     

胞内抗体及其研究进展

胞内抗体是指在细胞内表达并被定位于亚细胞区室的一类新的工程抗体。目前胞内抗体的研究主要集中于ScFv,ScFv基因结构简单,易导入细胞内表达且便于体外重组操作。胞内抗体作为一种新的基因治疗工具,在肿瘤基因治疗、人艾滋病基因治疗的实验研究及潜在的临床治疗方面展示了广泛的应用前景。同时,胞内抗体可以用作分析靶蛋白功能的研究工具,是对传统的“基因剔除”转基因动物的一种有效补充。现从胞内抗体的设计及载体选择、肿瘤基因治疗、人艾滋病基因治疗等方面对胞内抗体的研究进展进行综述。     

大蒜芥属一新变种

发表了大蒜芥属一新变种,无毛全叶大蒜芥(Sisymbrium luteum (Maxim.)O. E. Schulz var. glabrum F. Z. Li et Z. Y. Sun.)。